Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 22

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
Issuance of common stock, net of issuance costs50,664 5 215,108 — — 215,113 Net loss— — — — (6,755,356)(6,755,356)Foreign currency translation adjustments— — — (39,227)— (39,227)Balance at March 31, 20248,381,825 $838 $167,391,262 $(400,123)$(177,991,387)$(10,999,410)Stock-based compensation— — 562,719 — — 562,719 Issuance of common stock, net of issuance costs42,583 4 182,974 — — 182,978 Reverse stock split adjustment121,953 12 (12)— — — Net income— — — — 12,910,656 12,910,656 Foreign currency translation adjustments— — — 14,563 — 14,563 Balance at June 30, 20248,546,361 $854 $168,136,943 $(385,560)$(165,080,731)$2,671,506 

See accompanying notes.

4

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited) 

Six months ended June 30,20252024Cash flows from operating activitiesNet (loss) income$(8,394,790)$6,155,300 Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:Depreciation and amortization618,185 26,215 Deferred financing cost amortization11,622 21,875 Right-of-use asset - operating lease251,291 232,122 Stock-based compensation736,375 1,190,418 Loss on disposal of property and equipment— 600,000 Non-cash royalty revenue related to sale of future royalties(4,255)(22,438)Non-cash interest expense125,387 170,864 Changes in operating assets and liabilities:Accounts receivable — (27,979)Other receivables41,866 75,016 Prepaid expenses469,750 2,605,983 Deposits— 683,370 Other non-current